Delivery Order SPE2DB22D2006-SPE2DB25FW4CH
- Not listed
- The Defense Logistics Agency awarded a $5,935.94 delivery order to AmerisourceBergen Drug Corp for 50 mg vials of Activase, a thrombolytic medication used in acute medical situations. The contract was competitively awarded without set-aside restrictions and carries a firm fixed price structure with an ultimate completion date of September 11, 2025. AmerisourceBergen will perform this delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $13,058.92 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Activase, a tissue plasminogen activator used for thrombolytic therapy in acute medical emergencies. Issued on September 8, 2025, with completion expected by September 9, 2025, this firm fixed-price contract represents a non-competitive delivery order under the company's existing indefinite delivery contract vehicle. The order will be fulfilled at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $35,956.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Activase, a thrombolytic medication used in acute medical emergencies. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a competitively awarded, non-set-aside order fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Activase 50 mg vials, a thrombolytic medication used in acute medical emergencies. This firm fixed-price delivery order, valued at $3,563.99, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency (DLA) awarded a $11,854.88 delivery order to AmerisourceBergen Drug Corp for the supply of 50 mg vials of Activase, a tissue plasminogen activator used for thrombolytic therapy in acute medical emergencies. This firm fixed-price delivery order, issued on December 6, 2024, with an ultimate completion date of December 9, 2024, was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfilled...
- The Defense Logistics Agency awarded a $35.5K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Activase 100 mg vials, with completion scheduled for September 10, 2025. The contract is unclassified as a set-aside and represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $20,455.11 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Activase 50 mg vials, with an ultimate completion date of August 15, 2025. This is a firm fixed-price, non-set-aside contract issued to the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of ACTIVASE 50 mg vials, valued at $8,903.91, with a firm fixed price arrangement. This contract, issued on August 5, 2025, represents a direct fulfillment order with an ultimate completion date of August 6, 2025. The award was not set-aside and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,875.45 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed-price contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive, non-set-aside award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4CHDelivery Order
The Defense Logistics Agency awarded a $36,187.73 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Activase, a thrombolytic medication used in acute medical treatment. This competitively awarded, firm fixed-price contract was issued on September 9, 2025, with an ultimate completion date of September 10, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical supplier that serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. As a prime contractor, the company maintains an extensive portfolio of pharmaceutical and medical supply deliveries through competitive awards with the DLA Medical Supply Chain. The SPE2DX contract encompasses specialty medications, brand-name and generic drugs, vaccines, and other therapeutic commodities to support military healthcare operations worldwide. This particular delivery order exemplifies the company's role in fulfilling specialized pharmaceutical procurement requirements within the broader context of federal medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.2k | 9/9/25 |